Savara Inc. Class Action: Key Deadlines and Next Steps
Important Class Action Details for Savara Inc. Investors
Bragar Eagel & Squire, P.C. is encouraging Savara Inc. investors who have suffered losses to reach out to discuss their legal options. It's vital for affected investors to be aware of the deadlines and their rights regarding the ongoing class action case.
Timeline for Investor Action
If you purchased or acquired securities in Savara during the period from March 7, 2024, to May 23, 2025, it’s crucial that you understand you have until November 7, 2025, to file your application with the Court to be appointed as lead plaintiff in this lawsuit.
What You Need to Know
During this period, the law firm has filed a class action lawsuit against Savara Inc. (NASDAQ: SVRA) in the United States District Court for the Eastern District of Pennsylvania. This lawsuit is on behalf of all investors who acquired Savara securities during the specified dates.
Key Allegations in the Lawsuit
The complaint outlines several serious allegations against Savara. It claims that the company failed to disclose critical information regarding their Biologics License Application (BLA) for the drug MOLBREEVI. Specifically, the allegations suggest that the BLA lacked sufficient details about the drug's chemistry, manufacturing, and controls, leading the FDA to doubt the application’s completeness.
Impact on Shareholders
On May 27, 2025, following the announcement regarding the refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price fell significantly, losing 31.69% in value. This sharp decline emphasized the need for transparency from companies about regulatory processes that can dramatically affect investor interests.
Next Steps for Affected Investors
If you belong to the group of investors who acquired shares of Savara during the class period, it’s recommended to reach out for legal advice. Bragar Eagel & Squire, P.C. offers consultations for those who wish to explore their legal options related to the ongoing class action.
How to Get in Touch
To discuss your case or get more information, contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire, P.C. You can reach them by calling (212) 355-4648 or through email to investigate your potential claims.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a reputed law firm known for advocating the rights of investors. With a presence in New York, California, and South Carolina, they provide legal representation for individuals in various litigation matters, including securities law.
Frequently Asked Questions
What is the deadline to join the Savara class action?
The deadline for investors to apply to be a lead plaintiff is November 7, 2025.
How can I participate in the class action?
Investors can contact Bragar Eagel & Squire, P.C. to discuss their legal rights and participation.
What are the allegations against Savara?
The allegations state that Savara misled investors about the readiness of its Biologics License Application, leading to significant financial losses.
What should I do if I lost money on Savara stocks?
If you suffered losses, contact the law firm to explore your options for pursuing a claim.
Is there any cost to consult with the law firm?
Consultations are offered without any cost or obligation to you.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.